Documents

Q1 FY 2027 delivered double-digit growth, strong pharma momentum, and robust cash position.

Strong FY 2026 growth, high margins, and strategic moves set the stage for future expansion.

Q3 FY26 revenue up 10.2% YoY; strong margins, rising exports, and new biologics launch ahead.

Record revenue, strong margins, and capacity expansion drive robust growth across key segments.

Record quarterly revenue and profit growth, strong margins, and robust export performance.

FY2025 revenue up 19.1% YoY, margins strong, and major biologics CDMO expansion planned.

Q3 FY25 saw robust profit growth and a strategic business divestment boost for Vimta Labs.

Q2 FY25 revenue up 26.4% YoY, margins at 35.8%, with pharma driving growth and strong FY26 outlook.

Capacity expansion and operational focus position the business for strong growth by FY26.